https://pharmadevicenews.com/lillys-retatrutide-cut-knee-pain-as-weight-fell-nearly-29-but-the-phase-3-result-raises-a-bigger-osteoarthritis-question/ PharmaDeviceNews en 2026-11-09T16:40:35+00:00 Lilly’s retatrutide cut knee pain as weight fell nearly 29%, but the Phase 3 result raises a bigger osteoarthritis question American College of Rheumatology, Eli Lilly and Company, retatrutide, tirzepatide, TRIUMPH-4, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-24-2026-09_04_19-AM-e1790220895114.webp https://pharmadevicenews.com/innovents-sintbilo-cuts-ldl-by-up-to-65-as-it-targets-first-line-monotherapy-label/ PharmaDeviceNews en 2026-11-09T16:35:21+00:00 Innovent’s Sintbilo cuts LDL by up to 65% as it targets first-line monotherapy label CREDIT-5, Innovent Biologics, National Medical Products Administration, Peking University Third Hospital, Sintbilo, tafolecimab https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/can-johnson-johnsons-oral-icotyde-compete-with-biologics-in-psoriatic-arthritis/ PharmaDeviceNews en 2026-11-09T07:18:25+00:00 Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis? American College of Rheumatology, Bristol Myers Squibb, deucravacitinib, guselkumab, ICONIC-PsA 1, icotrokinra, ICOTYDE, Johnson & Johnson, Protagonist Therapeutics, Sotyktu, TREMFYA https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/cesalatamig-controlled-disease-in-90-at-its-chosen-dose-is-oncoc4-ready-for-a-pivotal-nsclc-test/ PharmaDeviceNews en 2026-11-09T07:06:08+00:00 Cesalatamig controlled disease in 90% at its chosen dose. Is OncoC4 ready for a pivotal NSCLC test? AI-081, BiPAVE-001, cesalatamig, OncoC4, Society for Immunotherapy of Cancer, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-19-2026-08_01_16-PM-e1789828314671.webp https://pharmadevicenews.com/novartis-lowered-a-major-inherited-heart-risk-marker-by-78-why-did-patients-not-benefit/ PharmaDeviceNews en 2026-11-08T16:52:26+00:00 Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit? American Heart Association, Amgen, Eli Lilly and Company, Ionis Pharmaceuticals, lepodisiran, Lp(a)HORIZON, Novartis, olpasiran, pelacarsen https://pharmadevicenews.com/wp-content/uploads/2026/05/Ribos-RBD1119-Phase-2-filing-puts-siRNA-antithrombotics-into-sharper-cardiovascular-focus-e1779979227353.webp https://pharmadevicenews.com/rybrevant-faspro-shrank-tumours-in-42-of-heavily-treated-head-and-neck-cancer-patients-can-phase-3-confirm-the-benefit/ PharmaDeviceNews en 2026-11-08T16:46:31+00:00 Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit? amivantamab, Halozyme Therapeutics, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Natera-expands-Signatera-evidence-with-head-to-head-Merkel-cell-carcinoma-study-e1784720429133.webp